12 December 2019 in Inflammation
1 January 2024 in Allergy, Asthma & Immunology Research
Zhang D, et al. Allergy Asthma Immunol Res. 2024 Jul;16(4):399-421. https://doi.org/10.4168/aair.2024.16.4.399
17 June 2025 in Cell Proliferation
The inflammatory storm is a hallmark of acute respiratory distress syndrome (ARDS), yet effective therapies remain unavailable. FK506‐binding protein 51 (FKBP5) has emerged as a regulator of inflammatory responses. In this study, FKBP5 expression was markedly increased in patients with sepsis and correlated with both cytokine levels and disease severity. Using sepsis‐induced ARDS models in Fkbp5
−/−
and bone marrow chimeric mice, this study demonstrated that non‐haematopoietic FKBP5 mitigates inflammatory injury. Single‐cell transcriptomic analysis identified fibroblasts and epithelial cells as the primary sources of non‐haematopoietic FKBP5 in the lung injury. Conditional deletion of FKBP5 in fibroblasts ( Col1a2 ‐iCre Fkbp5 flox/flox ) confirmed the essential role of fibroblast FKBP5 in the inflammatory response during ARDS. Mechanistically, FKBP5‐mediated necroptosis of alveolar fibroblasts triggered NF‐κB activation, proinflammatory cytokine release, neutrophil recruitment, and the establishment of an inflammatory microenvironment in alveolar epithelial tissue. These findings suggest a potential therapeutic strategy targeting fibroblast FKBP5 and provide a foundation for future clinical investigation in ARDS management.
18 October 2023 in Journal of Proteome Research
Inflammation plays an important role in the development of sepsis-acute respiratory distress syndrome (ARDS). Olink inflammation-related biomarker panels were used to analyze the levels of 92 inflammation-related proteins in plasma with sepsis-ARDS (n = 25) and healthy subjects (n = 25). There were significant differences in 64 inflammatory factors, including TNFRSF11B in sepsis-ARDS, which was significantly higher than that in controls. Functional analysis showed that TNFRSF11B was closely focused on signal transduction, immune response, and inflammatory response. The TNFRSF11B level in sepsis-ARDS plasma, LPS-induced mice, and LPS-stimulated HUVECs significantly increased. The highest plasma concentration of TNFRSF11B in patients with sepsis-ARDS was 10-20 ng/mL, and 10 ng/mL was selected to stimulate HUVECs. Western blot results demonstrated that the levels of syndecan-1, claudin-5, VE-cadherin, occludin, aquaporin-1, and caveolin-1 in TNFRSF11B-stimulated HUVECs decreased, whereas that of connexin-43 increased in TNFRSF11B-stimulated HUVECs. To the best of the authors' knowledge, this study was the first to reveal elevated TNFRSF11B in sepsis-ARDS associated with vascular endothelial dysfunction. In summary, TNFRSF11B may be a new potential predictive and diagnostic biomarker for vascular endothelium damage in sepsis-ARDS.
1 January 2022 in Allergy, Asthma & Immunology Research
Zhang J, et al. Allergy Asthma Immunol Res. 2022 Mar;14(2):233-253. https://doi.org/10.4168/aair.2022.14.2.233
16 January 2024 in Allergy